Briacell Therapeutics financials
$4.08−1.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Apr 30 | Q2 '26 Jan 31 | Q1 '26 Oct 31 | Q4 '25 Jul 31 | Q3 '25 Apr 30 | Q2 '25 Jan 31 | Q1 '25 Oct 31 | Q4 '24 Jul 31 | Q3 '24 Apr 30 | Q2 '24 Jan 31 | Q1 '24 Oct 31 | Q4 '23 Jul 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$7.6M | -$7.5M | -$8.3M | -$8.6M | -$6.3M | -$7.2M | -$5.2M | -$5.8M | -$9.2M | -$9.8M | -$8.5M | -$7.7M |
| Net income | -$7.2M | -$7.2M | -$8.2M | -$8.1M | -$6.1M | -$6.3M | -$5.8M | -$1.2M | $1.7M | -$11.3M | $6.0M | -$2.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.99 | $-2.58 | $-4.35 | $-9.28 | $-16.42 | $-23.31 | $-32.67 | $-0.03 | $1.61 | $-10.64 | $-0.50 | $-0.15 |
| EBITDA | -$7.6M | -$7.5M | -$8.3M | -$8.5M | -$6.3M | -$7.1M | -$5.1M | -$5.7M | -$9.2M | -$9.8M | -$8.5M | -$7.7M |
| Operating cash flow | -$7.0M | -$8.0M | -$7.7M | -$8.1M | -$7.2M | -$5.9M | -$7.0M | -$4.0M | -$8.8M | -$7.4M | -$7.6M | -$10.9M |
| Free cash flow | -$7.1M | -$8.0M | -$7.7M | -$8.1M | -$7.2M | -$5.9M | -$7.0M | -$4.5M | -$8.8M | -$7.4M | -$7.6M | -$10.9M |
| Diluted shares | 7.3M | 2.8M | 1.9M | 0.9M | 0.4M | 0.3M | 0.2M | 47.0M | 1.1M | 1.1M | 16.7M | 15.9M |
Balance sheet
| Period end | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 | Jan 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.9M | $29.9M | $2.7M | $10.5M | $12.5M | $5.0M |
| Short-term investments | $15.9M | $0.00 | $7.5M | $7.4M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $27.1M | $33.6M | $13.1M | $21.6M | $17.0M | $9.4M |
| Total liabilities | $3.7M | $3.4M | $3.7M | $4.3M | $5.1M | $6.1M |
| Shareholders' equity | $23.4M | $30.2M | $9.4M | $17.3M | $11.9M | $3.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology